Role of PPARγin Treatment of Diabetic Nephropathy by Telmisartan / 医药导报

ABSTRACT

Objective To demonstrate the mechanisms underlying the efficacy of telmisartan in diabetic nePhroPathy, and discuss the role of PPARγin this Process. Methods The diabetic nePhroPathy rat models were established and randomly assigned to control grouP, telmisartan grouP ( 5 mg · kg-1 · d-1 ) and combination of telmisartan and PPARγ inhibitor grouP (telmisartan5 mg·kg-1·d-1;GW96620. 5 mg·kg-1·d-1). After 12 weeks of treatment,the biochemical indexes of blood and urine,kidney weight,renal Pathology in each grouP of diabetic nePhroPathy rats were measured and comPared. The leVels of IL_1,IL_6 and TNF_α in blood of each grouP were detected by ELISA and comPared. The leVels of HGF and actiVated NF_κB (P65) in renal tissue of each grouP were detected by Western blotting and comPared. Results In diabetic nePhroPathy rats, telmisartan lowered the leVels of serum glucose, serum creatinine, urinary Protein and kidney weight, decreased the glomerular Volume,mesangial Proliferation and inflammatory cell infiltration,reduced blood leVels of IL_1,IL_6,and TNF_α,and decreased leVel of actiVated NF_κB (P65) in renal tissue. The leVel of HGF in renal tissue was eleVated by telmisartan. NeVertheless,these changes were Partly reVersed by PPARγ inhibitor GW9662. Conclusion PPARγ Presents an imPortant role in treatment of diabetic nePhroPathy by telmisartan.